Release issued 7th July 2004

Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that a variety of barriers may hinder the sales of radioimmunotherapies in the aggressive non- Hodgkin's lymphoma drug market.

"Companies investigating radioimmunotherapies to treat aggressive non-Hodgkin's lymphoma--such as Corixa/GlaxoSmithKline and Biogen Idec--will continue to struggle to overcome multiple barriers to uptake, including coordination difficulties between oncologists and the nuclear medicine physicists who will administer these therapies; regulatory and reimbursement challenges; and, certainly most significant in the United States, referral disincentives for office-based oncologists," said Mary Fletcher-Louis, analyst at Decision Resources.

According to the new Pharmacor study entitled Non- Hodgkin's Lymphoma, results of a forthcoming head-to-head trial between two radioimmunotherapies, 90Y-ibritumomab and 131I-tositumomab, in the indolent non-Hodgkin's lymphoma setting and sponsored by Corixa/GlaxoSmithKline, will be the principal determinant of market share distribution between the two agents.

About Non-Hodgkin's Lymphoma: Non-Hodgkin's lymphomas constitute the fifth most common cancer in the United States. In terms of pharmaceutical sales, non-Hodgkin's lymphoma ranks fourth after breast cancer, non-small-cell lung cancer, and colorectal cancer. Approximately 40% of non-Hodgkin's lymphomas follow an indolent course; the remaining non-Hodgkin's lymphomas are aggressive tumors.

About Pharmacor from Decision Resources: Pharmacor is a unique family of studies that assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources: Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

www.decisionresources.com

###

All company brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

(30th October 2009) Patient-targeted messaging for Emerging Multiple Sclerosis agents needs to highlight efficacy and preservation of quality of life

(26th October 2009) Continued uptake of Tnf-Alpha Inhibitors and Interleukin Inhibitors will drive US $2.2 billion growth in the Psoriasis drug market

(22nd October 2009) Tnf-Alpha Inhibitors will continue to dominate first- and second-line Biologic Therapy for the treatment of Rheumatoid Arthritis through 2011

(21st October 2009) Majority of surveyed physicians prescribe Cymbalta and Lyrica for treatment of Fibromyalgia but neither agent has the majority of its uses in first line

(15th October 2009) Sales of Glaxosmithkline’s Relenza likely to increase during the A/H1N1 2009 pandemic as Tamiflu-Resistant Strains of the virus spread